KDC-MN-176 – Kodiac biolabs

Plain-language summaryIntrigue 52 / 100

Ginkgo biloba is a maidenhair tree leaf extract widely used for cerebral circulation and cognitive function. The ginkgolides and bilobalides are the principal active compounds. Used historically for stroke and dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

26/100

Overhyped cognitive herb whose flagship dementia indication failed large RCTs; narrow PAF antagonist probe value remains

Look, ginkgo biloba is one of the most studied herbals on the planet, and that’s actually part of the problem. When you have thirty years of serious clinical work on a compound and the headline result is two large negative trials, you dont have a promising research target. You have a cautionary tale about wishful mechanism extrapolation.

The chemistry is genuinely interesting at the level of pharmacognosy. EGb 761, the standardized European extract, delivers roughly 24 percent flavonoid glycosides and 6 percent terpene lactones, with ginkgolides A, B, and C plus bilobalide carrying most of the pharmacological weight. Ginkgolide B is a real platelet-activating factor antagonist, and thats the mechanism that generated the most optimism for decades. Add modest MAO inhibition and broad antioxidant activity, and you have a plausible story for cerebrovascular and cognitive effects. On paper.

The problem is that on paper is where the dementia story largely stayed. The GEM trial (DeKosky et al., JAMA 2008) randomized over 3,000 community-dwelling older adults and found no reduction in dementia incidence versus placebo. GuidAge (Vellas et al., Lancet Neurology 2012) ran for five years in a high-risk population of older adults with spontaneous memory complaints and found the same: no effect on conversion to Alzheimer’s. Two large, multi-site, well-funded randomized trials. Both negative on primary endpoints. The evidence quality is high in the sense that the trials were methodologically competent; the translational signal is poor in the sense that the compound didn’t move what mattered.

There’s a more defensible case for peripheral arterial disease. Cochrane meta-analyses on intermittent claudication find a modest walking-distance benefit, which tracks more cleanly with the PAF antagonism story than the cognitive angle ever did. But modest improvement in claudication walking distance is not a frontier research question in 2026.

We don’t see a compelling case for featuring ginkgo prominently in an active research program. Ginkgolide B retains some use as a reference PAF antagonist if your question is specifically about platelet-activating factor biology, but cleaner, more selective PAF antagonists exist for that purpose. Everything else about ginkgo is either exhaustively characterized or definitively addressed by trials that came back empty. The compound earns its place in pharmacognosy textbooks. It doesn’t earn a high spot in a library built around compounds where the frontier is still genuinely open.

Novelty: 15
Mechanism promise: 20
In-category differentiation: 15
Evidence quality: 60
Translational signal: 28
Research bench value: 25

Rationale Ginkgo’s PAF antagonism and antioxidant chemistry are real but decades-old, and the GEM and GuidAge trials decisively closed the dementia prevention question; the common OTC herb cap of 35 would apply categorically but the raw calculation lands at 26, making it moot.

Maidenhair tree leaf extract

Standardized extract of Ginkgo biloba leaves used for cognitive function and peripheral circulation, characterized by flavonoid glycosides and terpene lactones.

Abstract

Ginkgo biloba is the world’s oldest living tree species, with leaves used in traditional Chinese medicine and standardized extracts (EGb 761) marketed in Europe for cognitive impairment and peripheral arterial disease. Active constituents are flavonoid glycosides (24 percent in EGb 761) and terpene lactones (ginkgolides A, B, C; bilobalide; 6 percent). Pharmacology includes platelet activating factor (PAF) antagonism (ginkgolides), MAO inhibition (modest), and antioxidant activity. The clinical evidence base in dementia is mixed (large GEM and GuidAge trials negative); peripheral arterial disease evidence is more positive. Doses are typically 120 to 240 mg of standardized extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-176Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-176

Ginkgo Biloba

Abstract

Read the full monograph